Assessing Second-Line Diabetes Agents for at Risk for Major Osteoporotic Fractures Case Study (Beta Cells 5- Knighten Health)

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, family physicians, general practitioners and healthcare professionals who treat patients with diabetes.

Learning Objectives

Upon completion of this educational activity, learners will be able to:
  • Recognize factors associated with fracture risk in patients with type 2 diabetes mellitus (T2DM) 
  • Discuss the benefits and limitations of currently approved type 2 diabetes drug classes for patients with osteoporosis or at risk for major osteoporotic fracture (MOF) 
  • Explain how to assess and integrate appropriate diabetes agents for patients with T2DM at risk for MOF based on medical history, personal preferences, and glycemic goals 
  • Understand how to develop patient-centric management plans to maximize adherence and glycemic control, and minimize fracture risk

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Topic Area: 
Bone and Calciotropic Hormones
Diabetes and Glucose Metabolism
Level of Outcomes: 
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 6 (Patient Health)
Activity summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credits
Course opens: 
Course expires: 
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The following faculty reported relevant financial relationships:
Doron Schneider, MD: Consultant, Janssen Pharmaceuticals, Inc., Lilly USA, LLC, Novo Nordisk Inc.
Ann V. Schwartz, PhD, MPH: Advisory board member, Amgen
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 0.50 AMA PRA Category 1 Credits